Cyclophosphamide/fludarabine/rituximab: Agranulocytosis: case report.

Also, he developed chemotherapy-related grade-III agranulocytosis [ I durations of treatments to reactions onsets not stated i ]. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 67-year-old man developed agranulocytosis while receiving chemotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukaemia (CLL). Prior to chemotherapy, he was also started on unspecified anti HBV-drugs (Hepatitis-B core antibody and hepatitis-B surface antibody were positive). [Extracted from the article]